Search
Dofetilide
go.drugbank.com/drugs/DB00204ApprovedInvestigationalDofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation
Urokinase
go.drugbank.com/drugs/DB00013ApprovedInvestigationalWithdrawn[A191943] Urokinase was granted FDA approval on 16 January 1978.[L12138]
Eszopiclone
go.drugbank.com/drugs/DB00402ApprovedInvestigationalEszopiclone was initially approved by the FDA in 2004.[L6769] … One major benefit of eszopiclone is that it is approved by the FDA for the long-term treatment of insomnia.
Niraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigational[A253248] First approved by the FDA on March 27, 2017,[A253912] niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. … [L43747] On December 12, 2025, the FDA expanded niraparib and abiraterone acetate (AKEEGA) with prednisone for the treatment of patients with BRCA2-mutated metastatic castration-sensitive prostate cancer
Cethromycin
go.drugbank.com/drugs/DB06419Investigational[L14006, A203369] However, after completing phase III clinical trials, it was deemed safe but not sufficiently efficacious by the FDA. … [A203369] Since this time, cethromycin has received FDA orphan drug designations for the prophylactic treatment of anthrax inhalation, plague due to _Yersinia pestis_, and tularemia due to _Francisella
Riboflavin
go.drugbank.com/drugs/DB00140ApprovedInvestigationalNutraceuticalVet approvedNutritional factor found in milk, eggs, malted barley, liver, kidney, heart, and leafy vegetables. The richest natural source is yeast. It occurs in the free form only in the retina of the eye, in whey, and in urine; its principal forms ...
Mixtures: CR-FRAN JARABE, Nephron FADiazoxide
go.drugbank.com/drugs/DB01119ApprovedInvestigationalFDA-approved therapy for this condition. … In September 2015, the FDA issued a safety alert regarding post-marketing reports of pulmonary hypertension occurring in infants and neonates.
Upadacitinib
go.drugbank.com/drugs/DB15091ApprovedInvestigational[A189165] The FDA approved upadacitinib in August 2019 and it is used for the treatment of active rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, and ankylosing spondylitis
Chloramphenicol succinate
go.drugbank.com/drugs/DB07565Approved[L14174] Chloramphenicol succinate was granted FDA approval on 20 February 1959.[L12711]